

Maria Cantonetti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9376927/publications.pdf>

Version: 2024-02-01

75
papers

1,758
citations

257450

24
h-index

289244

40
g-index

75
all docs

75
docs citations

75
times ranked

2595
citing authors

#	ARTICLE	IF	CITATIONS
1	Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients. <i>Biomedicines</i> , 2022, 10, 443.	3.2	4
2	Genetically Driven CD39 Expression Affects Sezary Cell Viability and IL-2 Production and Detects Two Patient Subsets with Distinct Prognosis. <i>Journal of Investigative Dermatology</i> , 2022, 142, 3009-3019.e9.	0.7	4
3	Vitamin D and non-Hodgkin lymphomas, trends from an Italian monocentric study. <i>Panminerva Medica</i> , 2021, 63, 547-549.	0.8	1
4	Preclinical Evidence for Targeting PI3K/mTOR Signaling with Dual-Inhibitors as a Therapeutic Strategy against Cutaneous T-Cell Lymphoma. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1045-1053.e6.	0.7	19
5	Preliminary results of a counselling programme for fertility preservation in female cancer patients: The experience of the GEMME DORMIENTI network. <i>European Journal of Cancer Care</i> , 2020, 29, e13174.	1.5	3
6	Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab. <i>Frontiers in Immunology</i> , 2020, 11, 579894.	4.8	4
7	The neutrophil to lymphocyte ratio (NLR) and the presence of large nodal mass are independent predictors of early response: A subanalysis of the prospective phase II PET-adapted HD0607 trial. <i>Cancer Medicine</i> , 2020, 9, 8735-8746.	2.8	10
8	Consolidation Radiotherapy Could Be Safely Omitted in Advanced Hodgkin Lymphoma With Large Nodal Mass in Complete Metabolic Response After ABVD: Final Analysis of the Randomized GITIL/FIL HD0607 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3905-3913.	1.6	36
9	A case of metachronous peripheral T-cell non-Hodgkin lymphoma following chemotherapy for Hodgkin disease successfully treated with brentuximab vedotin. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 1353-1356.	0.5	2
10	IgM-Secreting Diffuse Large B-Cell Lymphoma (DLBCL) Is a Poor Prognostic Subset within the Non-Germinal-Centre-Type (GC-type): An Italian Multicentre Study. <i>Blood</i> , 2020, 136, 30-31.	1.4	0
11	Remission of an HHV8-related extracavitary primary effusion lymphoma in an HIV-positive patient during antiretroviral treatment containing dolutegravir. <i>AIDS Research and Therapy</i> , 2019, 16, 15.	1.7	8
12	The neutrophil/lymphocyte ratio ≥ 3.5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network "Rete Ematologica del Lazio per i Linfomi" (RELLI). <i>Leukemia and Lymphoma</i> , 2019, 60, 3386-3394.	1.3	11
13	DIAGNOSTIC PERFORMANCE AND SAFETY OF BRONCHOALVEOLAR LAVAGE IN THROMBOCYTOPENIC HAEMATOLOGICAL PATIENTS FOR ASPERGILLOSIS DIAGNOSIS: A MONOCENTRIC, RETROSPECTIVE EXPERIENCE.. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019065.	1.3	7
14	Psoriasiform sarcoidosis: an unusual variety. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2019, 154, 492-493.	0.8	0
15	Genetic analysis of erythrocytosis reveals possible causative and modifier gene mutations. <i>British Journal of Haematology</i> , 2019, 186, e100-e103.	2.5	2
16	Association between CMV and Invasive Fungal Infections After Autologous Stem Cell Transplant in Lymphoproliferative Malignancies: Opportunistic Partnership or Cause-Effect Relationship?. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1373.	4.1	15
17	Blood and skin-derived Sezary cells: differences in proliferation-index, activation of PI3K/AKT/mTORC1 pathway and its prognostic relevance. <i>Leukemia</i> , 2019, 33, 1231-1242.	7.2	28
18	Allogeneic hematopoietic stem cell transplantation in Primary Cutaneous T Cell Lymphoma. <i>Annals of Hematology</i> , 2018, 97, 1041-1048.	1.8	14

#	ARTICLE	IF	CITATIONS
19	Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study). <i>Oncologist</i> , 2018, 23, 1033-1038.	3.7	3
20	BEAM vs FEAM high-dose chemotherapy: retrospective study in lymphoma patients undergoing autologous stem cell transplant. <i>Bone Marrow Transplantation</i> , 2018, 53, 1051-1054.	2.4	4
21	Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 454-462.	1.6	169
22	Molecular Expression of bone marrow angiogenic factors, cell-cell adhesion molecules and matrix-metallo-proteinase plasma cellular disorders: a molecular panel to investigate disease progression. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2018, 10, e2018059.	1.3	5
23	Recurrent Sweet's syndrome in a patient with multiple myeloma. <i>Clinical Case Reports (discontinued)</i> , 2018, 6, 1958-1960.	0.5	1
24	Nephelometric assay of urine free light chains: an alternative and early clinical test for Bence-Jones protein quantification. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, e313-e315.	2.3	2
25	Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e401-e419.	0.4	61
26	Impact of IFN lambda 3/4 single nucleotide polymorphisms on the cytomegalovirus reactivation in autologous stem cell transplant patients. <i>PLoS ONE</i> , 2018, 13, e0200221.	2.5	6
27	The Amount of Apoptosis Predicts Outcome in Ibrutinib-Treated Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018, 132, 4397-4397.	1.4	3
28	Prognostic Value of Bone Marrow Tracer Uptake Pattern in Baseline PET Scans in Hodgkin Lymphoma: Results from an International Collaborative Study. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1249-1254.	5.0	27
29	Cryotherapy reduces oral mucositis and febrile episodes in myeloma patients treated with high-dose melphalan and autologous stem cell transplant: a prospective, randomized study. <i>Bone Marrow Transplantation</i> , 2017, 52, 154-156.	2.4	27
30	Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor. <i>Clinical Microbiology and Infection</i> , 2016, 22, 946.e1-946.e8.	6.0	25
31	Minimal tumour burden in haematological diseases: a step forward with quantitative assessment of Bence-Jones in nephelometry?. <i>British Journal of Haematology</i> , 2016, 175, 733-735.	2.5	5
32	A case of oral mycosis fungoides successfully treated by combination of alemtuzumab and chemotherapy. <i>Annals of Hematology</i> , 2016, 95, 153-154.	1.8	5
33	Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia. <i>Drugs of Today</i> , 2016, 52, 249.	1.1	18
34	Pre-treatment staging of multiple myeloma patients: comparison of whole-body diffusion weighted imaging with whole-body T1-weighted contrast-enhanced imaging. <i>Acta Radiologica</i> , 2015, 56, 733-738.	1.1	26
35	Brain metabolic changes in Hodgkin disease patients following diagnosis and during the disease course: An 18F-FDG PET/CT study. <i>Oncology Letters</i> , 2015, 9, 685-690.	1.8	16
36	Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients. <i>Oncologist</i> , 2015, 20, 1413-1416.	3.7	22

#	ARTICLE	IF	CITATIONS
37	Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments. <i>Leukemia Research</i> , 2015, 39, 1066-1070.	0.8	29
38	Initial Staging of Hodgkin's Disease. <i>Medicine (United States)</i> , 2014, 93, e50.	1.0	13
39	Factors affecting inpatient liver and mediastinal blood pool 18F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin's lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1123-32.	6.4	29
40	Surgical Management of Rhinosinusitis in Onco-Hematological Patients. <i>Clinical and Experimental Otorhinolaryngology</i> , 2014, 7, 302.	2.1	9
41	Is cerebral glucose metabolism affected by chemotherapy in patients with Hodgkin's lymphoma?. <i>Nuclear Medicine Communications</i> , 2013, 34, 57-63.	1.1	23
42	Comprehensive analysis of PTEN status in S�zary syndrome. <i>Blood</i> , 2013, 122, 3511-3520.	1.4	47
43	Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination. <i>Blood</i> , 2012, 120, 3222-3228.	1.4	85
44	Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. <i>British Journal of Haematology</i> , 2011, 152, 551-560.	2.5	127
45	Percutaneous osteoplasty in the treatment of extraspinal painful multiple myeloma lesions. <i>Supportive Care in Cancer</i> , 2011, 19, 957-962.	2.2	11
46	CLIP: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11). <i>Annals of Hematology</i> , 2011, 90, 401-408.	1.8	28
47	Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. <i>Cancer</i> , 2010, 116, 5667-5675.	4.1	14
48	Simultaneous occurrence of BCR/ABL1 and RUNX1/RUNX1T1 in a case of therapy-related acute myeloid leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2009, 195, 189-191.	1.0	4
49	Sezary syndrome in relapse after reduced intensity allogeneic transplant successfully treated with donor lymphocyte infusion. <i>Bone Marrow Transplantation</i> , 2009, 43, 347-348.	2.4	9
50	Pegylated Liposomal Doxorubicin, Bleomycin, Vinblastine and Dacarbazine (CBVD) in the Treatment of Advanced Primary Cutaneous Lymphomas.. <i>Blood</i> , 2009, 114, 3717-3717.	1.4	1
51	Cerebrospinal Fluid Flow Cytometry Analysis in Newly Diagnosed Aggressive Non-Hodgkin Lymphomas at High Risk for Leptomeningeal Disease: Result of a Multicentric Prospective Italian Study.. <i>Blood</i> , 2009, 114, 2919-2919.	1.4	0
52	Quality of Life in Elderly Patients with Essential Thrombocythemia.. <i>Blood</i> , 2009, 114, 4973-4973.	1.4	0
53	The Impact of Therapeutic Management and Prognostic Factors on the Outcome of Primary Cutaneous B-Cell Lymphomas (PCBCL) (IELSG 11 Study). <i>Blood</i> , 2008, 112, 3608-3608.	1.4	0
54	Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2006, 108, 853-861.	1.4	171

#	ARTICLE	IF	CITATIONS
55	O6-(4-Bromothienyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro. <i>Pharmacological Research</i> , 2006, 53, 317-323.	7.1	34
56	The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia. <i>Cancer</i> , 2005, 104, 2743-2752.	4.1	45
57	CNS and Cutaneous Involvement in Patients With Chronic Myeloid Leukemia Treated With Imatinib in Hematologic Complete Remission: Two Case Reports. <i>Journal of Clinical Oncology</i> , 2003, 21, 4256-4258.	1.6	17
58	Early Autologous Stem-Cell Transplantation Versus Conventional Chemotherapy as Front-Line Therapy in High-Risk, Aggressive Non-Hodgkin's Lymphoma: An Italian Multicenter Randomized Trial. <i>Journal of Clinical Oncology</i> , 2003, 21, 1255-1262.	1.6	117
59	Disseminated Pagetoid Reticulosis Presenting as Cytotoxic CD4/CD8 Double Negative Cutaneous T-cell Lymphoma. <i>Acta Dermato-Venereologica</i> , 2002, 82, 314-316.	1.3	7
60	Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors. <i>Transfusion and Apheresis Science</i> , 2002, 26, 103-110.	1.0	7
61	New reciprocal translocation t(6;10)(q27;q11) associated with idiopathic myelofibrosis and eosinophilia. <i>Leukemia Research</i> , 2001, 25, 349-351.	0.8	13
62	Systemic Therapy of Primary Cutaneous B-cell Lymphoma, Marginal Zone Type, with Rituximab, a Chimeric Anti-CD20 Monoclonal Antibody. <i>Acta Dermato-Venereologica</i> , 2001, 81, 207-208.	1.3	35
63	Short term treatment with <i>Escheria coli</i> recombinant human granulocyte-macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease. , 2000, 88, 454-460.		12
64	A Comparative Analysis of FISH, RT-PCR, and Cytogenetics for the Diagnosis of <i>bcr-abl</i> Positive Leukemias. <i>American Journal of Clinical Pathology</i> , 1998, 109, 24-31.	0.7	39
65	FISH analysis for CML monitoring. <i>Annals of Hematology</i> , 1996, 73, 113-119.	1.8	32
66	Cytogenetic analysis is non-informative for assessing the remission rate in chronic myeloid leukemia (CML) patients on interferon- γ (IFN- γ) therapy. <i>Cancer Genetics and Cytogenetics</i> , 1995, 84, 15-18.	1.0	20
67	MACOP-B vs F-MACHOP Regimen in the Treatment of High-Grade Non-Hodgkin's Lymphomas. <i>Leukemia and Lymphoma</i> , 1995, 16, 457-463.	1.3	16
68	Phase III Comparative Trial Using CHOP vs CIOP in the Treatment of Advanced Intermediate-Grade Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 1995, 19, 329-335.	1.3	28
69	Clinical implications of cytokine and soluble receptor measurements in patients with newly diagnosed aggressive non-Hodgkin's lymphoma. <i>European Journal of Haematology</i> , 1995, 54, 9-17.	2.2	41
70	Multiple skin tumors in long-term treatment with hydroxyurea. <i>European Journal of Haematology</i> , 1992, 48, 121-122.	2.2	14
71	Soluble factors levels in the initial staging of high-grade non-Hodgkin's lymphomas. <i>Haematologica</i> , 1992, 77, 518-21.	3.5	9
72	Non-Hodgkin lymphomas of the Central Nervous System. <i>Italian Journal of Neurological Sciences</i> , 1991, 12, 453-459.	0.1	0

#	ARTICLE	IF	CITATIONS
73	Intermediate-dose (25 mg/m ²) intravenous melphalan for patients with multiple myeloma in relapse or refractory to standard treatment. <i>European Journal of Haematology</i> , 1989, 42, 233-237.	2.2	16
74	Recombinant interferon alfa-2b (INTRON A) as post-induction therapy for responding multiple myeloma patients. M84 protocol. <i>Cancer Treatment Reviews</i> , 1988, 15, 43-48.	7.7	43
75	Treatment of multiple myeloma: A randomized study of three different regimens. <i>Leukemia Research</i> , 1985, 9, 1043-1049.	0.8	20